Catalent Announces Launch Of Private Offering Of $400 Million (U.S. Dollar Equivalent) Of Euro-Denominated Senior Unsecured Notes Due 2024

Catalent, Inc. ("Catalent") (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the "Catalent Operating Subsidiary"), intends to offer, subject to market and other conditions, $400 million (U.S. dollar equivalent) aggregate principal amount of euro-denominated senior unsecured notes due 2024 (the "Notes") in a private offering (the "Private Offering") that is exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act").

The Catalent Operating Subsidiary intends to use the net proceeds from the Private Offering to fund its acquisition of Accucaps Industries Limited, repay a portion of the outstanding borrowings under its senior secured credit facilities, plus any accrued and unpaid interest, pay related fees and expenses and provide cash on its balance sheet for general corporate purposes.

The Notes will be guaranteed by all of the wholly owned U.S. subsidiaries of the Catalent Operating Subsidiary that guarantee its senior secured credit facilities. The Notes will not be guaranteed by PTS Intermediate Holdings, LLC or Catalent, the direct and indirect parent companies of the Catalent Operating Subsidiary.

The Notes will be offered and sold to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act and outside the United States pursuant to Regulation S under the Securities Act.

The Notes have not been and will not be registered under the Securities Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Notes or any other securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation, or sale is unlawful.

If you liked this article you might like

With Hurricane Harvey, We Are in the Crosshairs of Volatility: Market Recon

Bullish and Bearish Reversals for the Week

2 Big Companies and 1 Small One to Target in the Pharma/Biotech Space

Catalent (CTLT) Stock Slumps on Secondary Stock Offering

No Fear of the Fed for Futures or in Asia